Evaluation of in vitro efficacy of recombinant FIX concentrates on thrombin generation in patient plasma. Thrombin-generation profiles on in vitro supplementation of Alprolix in (A) normal pooled plasma, (B) FIX-depleted plasma, (C) plasma of a hemophilia B carrier harboring p.(Gln96Arg), and (D-E) plasma of her 2 sons with hemophilia B. Thrombin-generation profiles on in vitro supplementation of Rixubis in (F) normal pooled plasma, (G) FIX-depleted plasma, (H) plasma of a hemophilia B carrier harboring p.(Gln96Arg), and (I-J) plasma of her 2 sons with hemophilia B. Thrombin-generation profiles on in vitro supplementation of Benefix in (K) normal pooled plasma, (L) FIX-depleted plasma, (M) plasma of a hemophilia B carrier harboring p.(Gln96Arg), and (N-O) plasma of her 2 sons with hemophilia B. Data were obtained by CAT assay with 1 pM TF for coagulation initiation. Dashed lines indicate the peak height in the control condition (pooled normal human plasma).